Thus, we attempted to determine whether inducing the degradation of YTHDF2 by inhibition of HSP90β may enhance the sensitivity of HCC cells to the targeted therapy with sorafenib. The gene discussed is HSP90AB1; the disease is hepatocellular carcinoma.